Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I/II study of CYH33 in PROS and PRVM
jRCT2041250168Phase 2Recruiting
- Sponsor
- Haihe
- Start
- Mar 2026
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 2, randomised, double-blind trial of risovalisib mesylate in PIK3CA-related overgrowth spectrum (PROS) and PIK3CA-related vascular malformation (PVM) (2 cohorts), sponsored by Haihe. Started Mar 2026; status: recruiting.
02
Drugs
risovalisib mesylate
03
Conditions
PIK3CA-related overgrowth spectrum (PROS)PIK3CA-related vascular malformation (PVM)
Beyond the preview
Go deeper on jRCT2041250168.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2041250168.